Is tucatinib/tucatinib included in medical insurance?

Tucatinib/Tucatinib (Tucatinib) is a highly selective oral tyrosine kinase inhibitor for HER2-positive breast cancer and its metastatic lesions. It was developed by Seagen Company of the United States. By inhibiting the HER2 signaling pathway, this drug has demonstrated significant potential in international clinical practice to extend survival and improve the prognosis of patients with brain metastases. However, as of now, tucatinib has not been officially launched in mainland China, so it has not been included in the national medical insurance directory, and there is no relevant local medical insurance reimbursement policy.

From the perspective of medical insurance access, drugs usually need to go through four stages to enter China's medical insurance catalog:"approval for marketing - clinical value assessment - negotiation of pricing - medical insurance access". Tucatinib has not yet completed the registration review process with the National Medical Products Administration (NMPA) of China, so it is still in the overseas marketing and domestic clinical research observation stages. Although domestic multi-center clinical trials have been launched one after another to provide basic data support for future official launch and medical insurance inclusion, in the short term, patients who need medication will mainly rely on overseas drug purchase channels or clinical research projects.

Internationally, tucatinib has been approved by the U.S. FDA and the European EMA for use in combination with trastuzumab and capecitabine for the treatment of HER2-positive advanced or metastatic breast cancer, including patients with brain metastases. Its clinical value lies in its "high specificity + low off-target effect" design, which can reduce common side effects such as rash and diarrhea while maintaining efficacy, thereby improving patients' long-term medication compliance.

In the future, asHER2-positive breast cancer treatment options develop towards precision and oral administration, tucatinib is expected to become a new generation of important targeted drugs after trastuzumab and pyrotinib. If it completes registration in China and passes medical insurance negotiations, the price is expected to drop significantly, thereby significantly reducing the financial burden on patients.

Reference materials:https://www.tukysa.com/